ConductScience.org, home

Trial · NCT04617171

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryTime to first exacerbation in patients with a severe asthma exacerbation with raised blood eosinophil countChange from baseline (Day 1) to 52 weeksTime to first exacerbation requiring either oral corticosteroid (OCS) use and/or an unscheduled visit to the Emergency Department or hospitalization
SecondaryTime to hospital readmission due to asthma exacerbation (Key Secondary outcome)Baseline (Day 1) to 52 weeksTime to hospital readmission due to asthma exacerbation
SecondaryRate of severe exacerbation (i.e. requiring admission to hospital for asthma exacerbation)Baseline (Day 1) to 52 weeksNUmber of severe exacerbation (i.e. requiring admission to hospital for asthma exacerbation)
SecondaryHospital LOS (index admission and subsequent admissions)Change from baseline (Day 1) to 52 weeksTotal hospital LOS
SecondaryNeed for Intensive Care Unit (ICU) admission with/without mechanical ventilation during the index admissionBaseline (Day 1) to index admission discharge dateICU admission during index admission
SecondaryHospital survival post admission (index admission)Baseline (Day 1) to index admission discharge dateHospital survival for index admission
SecondaryTotal OCS burdenBaseline (Day 1) to 52 weeksCumulative OCS dose
SecondaryTotal number of exacerbations requiring emergency healthcare utilization (including ED, polyclinic visits, Specialist outpatient visits)Baseline (Day 1) to 52 weeksTotal number of emergency healthcare utilization for exacerbations
SecondaryPre/post bronchodilator Forced Expiratory Volume 1s (FEV1), FVC, FEV1/FVC at baseline and at 52 weeksChange from baseline (Day 1) to 52 weeksChange in Pre/post bronchodilator Forced Expiratory Volume 1s (FEV1), FVC, FEV1/FVC
SecondaryBlood eosinophil counts (serial measurement over 52 weeks)Change from baseline (Day 1) to 52 weeksChange in blood eosinophils
SecondaryGINA assessment of symptom controlChange from baseline (Day 1) to 52 weeksChange in GINA assessment of symptom control ( Well controlled, Partly controlled or Uncontrolled)
SecondaryAsthma Control Questionnaire 7 (ACQ 7)Change from baseline (Day 1) to 52 weeks
Change in Asthma Control Questionnaire 7 (ACQ 7) Scores range from 0-6( higher is worse). A score of 0.0-0.75 is classified as well-controlled asthma; 0.75-1.5 is a grey zone; and \>1.5 is poorly controlled asthma. The minimum clinically important difference is 0.5
SecondarySt George's Respiratory Questionnaire (SGRQ)Change from baseline (Day 1) to 52 weeks
Change in St George's Respiratory Questionnaire (SGRQ) The SGRQ total score is made up of 2 parts : Part 1 addresses the frequency of respiratory symptoms and Part 2 addresses the patient's current state. Data is entered into the calculator and scores will be generated ( 0 to 100). The lower the score, the better.
OtherAdverse EventsChange from baseline (Day 1) to 52 weeksTo evaluate adverse events, serious adverse events

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04617171/registered